Position in SER
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$130,934
+$1,822 QoQ
Shares Held
67,492
0.0% QoQ
Ownership
0.450%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 65%
Shared 0%
None 35%
Common Shares in SER Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Waverly Advisors, LLC holds $22,088,789 across 17 Biotechnology names. SER ranks #13 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
23,055 | $10,294,979 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,895 | $4,554,712 | |
| 3 | SYRE |
Spyre Therapeutics, Inc.
|
25,966 | $1,309,725 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
38,218 | $1,243,613 | |
| 5 | EYPT |
EyePoint, Inc.
|
77,914 | $1,004,311 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
18,124 | $862,158 | |
| 7 | INCY |
Incyte Corp
|
8,242 | $775,737 | |
| 8 | EXEL |
Exelixis, Inc.
|
12,665 | $543,201 |
All Filings in SER
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $130,934 | 67,492 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $129,112 | 67,492 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $361,757 | 67,492 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $415,750 | 67,492 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $382,679 | 67,492 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $338,134 | 67,492 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $451,521 | 67,492 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $224,986 | 23,485 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||